Park Jeong-Hui, Kim Sun Jung, Grajeda Lily, Ramirez Alexiya, Chang Jongwha
Department of Health Behavior, School of Public Health, Texas A&M University, College Station, TX, USA.
Department of Health Administration and Management, College of Medical Science, Soonchunhyang University, Asan, Republic of Korea.
Clin Drug Investig. 2023 Aug;43(8):635-642. doi: 10.1007/s40261-023-01297-0. Epub 2023 Aug 4.
BACKGROUND AND OBJECTIVE: The number of hospitalizations due to opioid use disorders in the USA increased steadily from 62,010 in 1998-2000 to 136,240 in 2015-2016; however, no health care utilization of lung cancer patients with opioid use disorder has been reported. The purpose of this paper is to investigate health care utilization due to opioid use disorder among lung cancer patients and to investigate additional charge status due to this disorder.
The National Inpatient Sample of the USA was used to identify lung cancer patients (n = 11,418, weighted n = 557,090) from 2016 to 2020. The characteristics of patient samples, temporal trend of opioid use disorder, and its association with health care utilization measured by hospital charges were thoroughly examined by the multivariate survey linear regression model.
Among 557,090 lung cancer patients, 2.4% had opioid use disorder. The proportion of opioid use disorder among lung cancer patients during the study periods had continuously grown. Hospital charges also continued to increase during the study period and were higher among lung cancer patients with opioid use disorder. Survey linear results showed that opioid use disorder was associated with 12.6% higher hospital charges. Analysis of subgroups revealed that this trend was similar across p < the majority of social groups; however, it was significantly higher among Caucasian individuals (0.001) and self-pay groups (p = 0.035) than among others.
Research conducted has identified gaps in care in rural and suburban areas and a lack of equal care given to minority and low-income patients. These vulnerable groups access health care less often, are charged more for the care they receive, and often face multiple barriers to treatment. Unless these issues are addressed with a focus on socioeconomic factors, race, and region, the opioid epidemic will continue to negatively decimate these populations.
背景与目的:美国因阿片类药物使用障碍而住院的人数从1998 - 2000年的62,010人稳步增加到2015 - 2016年的136,240人;然而,尚未有关于患有阿片类药物使用障碍的肺癌患者的医疗保健利用情况的报道。本文旨在调查肺癌患者中因阿片类药物使用障碍导致的医疗保健利用情况,并调查因该障碍导致的额外费用状况。
使用美国国家住院样本识别2016年至2020年的肺癌患者(n = 11,418,加权n = 557,090)。通过多变量调查线性回归模型全面检查了患者样本的特征、阿片类药物使用障碍的时间趋势及其与以医院费用衡量的医疗保健利用的关联。
在557,090名肺癌患者中,2.4%患有阿片类药物使用障碍。研究期间肺癌患者中阿片类药物使用障碍的比例持续上升。研究期间医院费用也持续增加,且患有阿片类药物使用障碍的肺癌患者费用更高。调查线性结果显示,阿片类药物使用障碍与高出12.6%的医院费用相关。亚组分析表明,在大多数社会群体中(p < )这种趋势相似;然而,白种人个体(0.001)和自费群体(p = 0.035)中的这一比例明显高于其他群体。
已开展的研究发现农村和郊区存在护理差距以及少数族裔和低收入患者未得到平等护理的情况。这些弱势群体较少获得医疗保健服务,接受护理的费用更高,并且往往面临多种治疗障碍。除非关注社会经济因素、种族和地区来解决这些问题,否则阿片类药物流行将继续对这些人群造成负面重创。